Document Detail

Cardiac amyloidosis: evolving approach to diagnosis and management.
MedLine Citation:
PMID:  21989745     Owner:  NLM     Status:  PubMed-not-MEDLINE    
The systemic amyloidoses are a group of heterogeneous disorders characterized by extracellular deposition of misfolded fibrillar protein that results in organ dysfunction. Involvement of the heart (cardiac amyloidosis) is manifest by increased cardiac wall thickness and impairment of myocardial diastolic and systolic properties, changes that result in heart failure, dysrhythmia, and death. Amyloidosis is classified by precursor protein, with light-chain (AL) and transthyretin (TTR) disease being most common in the United States. TTR amyloid can result from misfolding of variant TTR, a genetically inherited disease, or wild-type TTR, an acquired form of disease (termed senile systemic amyloidosis). In recent years, advances in the diagnosis and treatment of cardiac amyloidosis include identification and validation of disease biomarkers, new imaging techniques, and consensus treatment guidelines. Elevations of B-type natriuretic peptide and cardiac troponins can identify cardiac amyloidosis with a high degree of precision and confer important prognostic information. Non-invasive cardiac imaging techniques, such as cardiac magnetic resonance imaging and echocardiography with strain quantification, afford the ability to diagnose cardiac amyloidosis most often without the need for a confirmatory heart biopsy. Treatment of heart failure resulting from cardiac amyloidosis differs in many respects from most other etiologies of cardiomyopathy. The mainstay of treatment involves volume control with diuretics, low dose β-adrenergic antagonists or amiodarone for dysrhythmia, and warfarin to prevent thromboembolism. Although widely held to have a dismal prognosis, modern treatments such as high-dose melphalan with stem cell transplantation (HDM/SCT) for AL disease achieve a complete hematologic response in nearly half of eligible patients and yield long-term survival. For patients with advanced AL cardiac amyloidosis, cardiac transplantation followed by HDM/SCT is also an option that has proven highly effective. For familial amyloid derived from variant TTR, liver transplantation is the one validated treatment; however, small molecule therapeutic agents now in clinical trials appear capable of slowing or halting TTR amyloid deposition.
Hans K Meier-Ewert; Vaishali Sanchorawala; John L Berk; Frederick L Ruberg
Related Documents :
22516205 - Twist factor regulation of non-cardiomyocyte cell lineages in the developing heart.
25450015 - Effects of right ventricular hemodynamic burden on intraventricular flow in tetralogy o...
882485 - Polyradiculoneuritis and mycoplasma pneumoniae infection.
1205705 - Estimated frequency of acute and chronic renal insufficiencies in a transdanubian regio...
22436925 - Wide variations in energy delivery using an impedance-controlled algorithm in bipolar r...
15127375 - Brugada syndrome with atypical ecg: downsloping st-segment elevation in inferior leads.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in cardiovascular medicine     Volume:  13     ISSN:  1534-3189     ISO Abbreviation:  Curr Treat Options Cardiovasc Med     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-03     Completed Date:  2011-11-10     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815942     Medline TA:  Curr Treat Options Cardiovasc Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  528-42     Citation Subset:  -    
Section of Cardiovascular Medicine and Amyloid Treatment and Research Program, Boston University School of Medicine, C-8, 88 East Newton Street, Boston, MA, 02118, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduced graphene oxide supported highly porous V(2)O(5) spheres as a high-power cathode material for...
Next Document:  Pericarditis and pericardial effusion: management update.